LMR Partners’s Arbutus Biopharma ABUS Stock Holding History

LMR Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100,000	Closed	-$258K	–	1091
2024 Q1	$258K	Buy	+100,000	New	+$259K	﹤0.01%	832

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return

BCP

BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

LMR Partners's ABUS Position: Q1 2025 in Review

LMR Partners sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 158,249 shares — an estimated $517K sold.

LMR Partners first reported a position in ABUS in Q1 2014 and held it in 21 quarters. The position peaked at $789K in Q2 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

LMR Partners reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 158,249 Arbutus Biopharma shares in Q1 2025, an estimated $517K.
LMR Partners first reported a position in Arbutus Biopharma in Q1 2014 and held it in 21 quarters.
LMR Partners's Arbutus Biopharma position peaked at $789K in Q2 2024.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.